Physician Resources
New Products/Product News
Am J Orthop. 2009 March;38(3):152-153
| Ferris Mfg. Corp. has introduced PolyMem WIC® Silver® Rope, a member of the PolyMem QuadraFoam family of dressings. Specially designed for use on cavity, undermining and tunneling wounds, PolyMem WIC Silver Rope contains a unique small-particle silver formulation to help protect the wound bed from microbial contamination. It is made from hydrophilic polyurethane membrane matrix that is reinforced for enhanced strength for use in deep tunneling wounds. According to Ferris Mfg. Corp., this reinforcement helps to allow easy and complete removal of the dressing at each dressing change. PolyMem WIC Silver Rope dressings can absorb up to six times their weight in exudate from the wound. There are many PolyMem QuadraFoam dressing configurations (with and without adhesive) available for use as a cover dressing with PolyMem WIC Silver Rope. All PolyMem QuadraFoam dressings contain a mild nonionic, nontoxic tissue-friendly cleansing agent, a moisturizer (glycerol), and a superabsorbent starch copolymer. These components allow PolyMem to continuously cleanse and moisturize the wound while in place. PolyMem QuadraFoam Silver dressings contain small-particle silver that releases silver ions as the dressing absorbs moisture and exudate. For more information on PolyMem WIC Silver Rope, contact Ferris Mfg. Corp. *Organisms tested included Klebsiella pneumoniae (ATCC# 4352), Pseudomonas aeruginosa (ATCC# 9027), Enterococcus faecalis (VRE) (ATCC# 51575), Candida albicans (ATCC# 10231), Staphylococcus aureus (MRSA) (ATCC# 33591) and Staphylococcus aureus (ATCC#6538). The organisms chosen demonstrate the antimicrobial actions of the silver formulation on relevant, representative organisms. |
Cymbalta Significantly Reduced Osteoarthritis Knee Pain in New Study
| In a new study, Cymbalta (duloxetine HCl) 60 -120 mg, taken once daily, reduced pain severity significantly, compared with placebo, in patients with osteoarthritis pain of the knee. Data from the 13-week randomized, double-blind, placebo-controlled clinical trial were presented at the annual meeting of the American Academy of Pain Medicine (AAPM) in Honolulu, Hawaii. Duloxetine-treated patients showed greater reductions from baseline on the primary endpoint, the 24-hour average pain score on the Brief Pain Inventory (BPI), compared with placebo-treated patients. In the study, 65% of duloxetine-treated patients experienced a clinically significant (at least 30%) improvement in pain, compared with 44% of placebo-treated patients. The duloxetine-treated patients also showed improved physical function, compared with placebo-treated patients, as measured by the Western Ontario and McMaster Osteoarthritis Index (WOMAC). In this study, patients on duloxetine did not show statistically significant improvements on the WOMAC |